Cost-effectiveness of the anti-fibrotics for the treatment of idiopathic pulmonary fibrosis in the United States
Abstract Background The anti-fibrotic medications nintedanib and pirfenidone were approved in the United States for use in patients with idiopathic pulmonary fibrosis several years ago. While there is a growing body of evidence surrounding their clinical effectiveness, these medications are quite ex...
Gardado en:
| Principais autores: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
BMC
2022-01-01
|
| Series: | BMC Pulmonary Medicine |
| Assuntos: | |
| Acceso en liña: | https://doi.org/10.1186/s12890-021-01811-0 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|